Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea’s (SIX: BSLN) milestone march continues
Published by Jyoti Prakash, CFA

Basilea has reported another US$1.25m milestone payment for partner Pfizer, triggered by Cresemba sales in the region crossing a pre-defined threshold. This is the fourth milestone payment for Cresemba from the region this year and adds to the already strong H2 performance (c CHF33m/c US$38.5m milestone payments recorded in H224 so far; CHF35m in 2024 to date). The Asia-Pacific region, and in particular China (which accounts for c 20% of the market potential for Cresemba), is of key importance to Basilea, as the company approaches maturity in the US and European markets (market exclusivity until late 2027). Note that Cresemba has recorded in market sales of US$505m for the 12-months ended June 2024, a 20% y-o-y growth.

 

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.